Research Article

Vascular Disrupting Agent Arsenic Trioxide Enhances Thermoradiotherapy of Solid Tumors

Figure 2

Equimolar comparison of arsenic trioxide and cisplatin as part of a recurring trimodality regimen every 4 days against FSaII fibrosarcoma tumors. As in the previous figure, in the dual- or trimodality treatment groups, radiation was given first, followed by ATO or cisplatin injection within 30 min and hyperthermia was applied beginning 2 h after the completion of radiation. 𝑁 = 6–8 mice per group. Error bars represent 1 SEM. INSET: histological evidence of antitumor effects of repeated trimodality therapy applied every 4 days, 3 times in total in FSaII tumors (tumors taken from treatment groups on the last day of measurement) compared to control tumor.
934918.fig.002a
(a)
934918.fig.002b
(b)